Monograph Details
|
|
Immune System
> Immunization
|
|
IMOVAX |
| Manufacturer |
|
Sanofi Pasteur, Inc. |
| Legal Classification |
|
Rx
|
| Generic Name |
|
Rabies vaccine 2.5Units/mL; grown in human diploid cell cultures (inactivated whole virus); inj. |
| Indications |
|
Preexposure immunization and postexposure treatment of rabies. |
| Adults and Children |
|
Preexposure: 3 inj of 1mL IM each on day 0, 7, and either day 21 or 28. Booster doses: 1mL every 2 yrs (see literature). Postexposure treatment: a 5 dose regimen of 1mL IM given on days 0, 3, 7, 14, 28 or 30 (WHO or ACIP recommendations), and 90 (give 1st dose with rabies immune globulin). If previously immunized against rabies, only 2 doses are given, immediately after exposure, and 3 days later (no rabies immune globulin needed). |
| Precautions |
|
Postpone preexposure immunization during acute febrile illness or infection. Immunocompromised: may get suboptimal response (monitor titers). Have epinephrine inj (1:1000) available. Pregnancy (Cat.C). |
| Interactions |
|
Immunosuppressants: may get suboptimal response. |
| Adverse Reactions |
|
Local reactions (pain, erythema, swelling), systemic reactions (nausea, headache, muscle aches, abdominal pain). |
| How Supplied |
|
Single-dose vial (1mL)—1 (w. syringe and diluent) |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
